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Introduction: Cefepime, a broad spectrum antibiotic, is commonly prescribed in intensive care units (ICU) and
may be an overlooked cause of neurologic symptoms such as encephalopathy, myoclonus, seizures, and coma.
We aimed to characterize cefepime neurotoxicity in the ICU.
Methods: We performed a retrospective study of adult ICU patients treated with intravenous cefepime for at least
3 days between January 1, 2009 and December 31, 2011. The primary outcome was the development of cefepime
neurotoxicity, with the likelihood of causality ascribed via a modified Delphi method.
Results: This study included 100 patients. The mean age was 65.8 years (± 12.7 years). The median daily average
dose of cefepime was 2.5 (IQR 2.0 to 3.5) grams. The median treatment duration was 6 (IQR 4 to 10) days. Renal
failure in any form was present in 84 patients. Chronic kidney disease affected 40 patients, and 77 had acute kidney
injury. Cefepime neurotoxicity occurred in 15 patients. Of these, seven were considered definite cases, three
probable, and five possible. Neurotoxic symptoms included impaired consciousness (n = 13), myoclonus (n = 11),
disorientation (n = 6), and nonconvulsive status epilepticus (n = 1). The dose of cefepime was appropriately
adjusted for renal clearance in 64 patients (75.3%) without cefepime neurotoxicity and four patients (28.6%) with
neurotoxicity (P = 0.001). Chronic kidney disease was present in 30 patients (35.3%) without neurotoxicity and in
10 (66.7%) of those with neurotoxicity (P = 0.04).
Conclusions: Critically ill patients with chronic kidney disease are particularly susceptible to cefepime neurotoxicity.
Myoclonus and impaired consciousness are the predominant clinical manifestations. Neurotoxic symptoms
occur more often when the cefepime dose is not adjusted for renal function, but can still occur despite those
modifications.Introduction
Potent, broad-spectrum antimicrobials are increasingly
prescribed in intensive care units (ICUs) because of the
proliferation of multidrug-resistant pathogens. Cefepime,
a fourth-generation cephalosporin, is one of these antimi-
crobials commonly prescribed empirically for nosocomial
infections. Because cefepime is predominantly renally
excreted (85% unchanged), a reduction in renal function
confers a proportional increase in the elimination half-life
and reduction in total body clearance of cefepime [1]. In
patients with renal failure, cefepime can accumulate in
both the blood and cerebrospinal fluid and reach toxic
concentrations [2]. Consequently, patients with renal* Correspondence: Rabinstein.alejandro@mayo.edu
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reproduction in any medium, provided the orfailure who are treated with cefepime at relatively high
doses are at risk of developing neurological symptoms that
include seizures, hallucinations, confusion, myoclonus,
and coma [3-12].
The terms ‘encephalopathy’ or ‘delirium’ generically
describe cerebral dysfunction of some type, but most of
the time they are used to characterize patients with a
change in attention, perception and memory. These
neurological manifestations are very poorly understood
considering their high prevalence in the ICU [13,14].
Given the pervasiveness of confounding causes of en-
cephalopathy (for example infection, postoperative state,
electrolyte disturbances, hypoglycemia, uremia, shock,
alcohol withdrawal, pain, hypercapnia, hypoxemia), elu-
cidating the cause of ‘altered mental status’ or ‘failure to
awaken’ in a patient in the ICU can be challenging. Des-
pite this etiologic uncertainty, the encephalopathy oftenLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apparent causation, assessment for potential medica-
tion toxicity may prove explanatory. Antibiotics can
cause neurologic symptoms, including penicillins,
cephalosporins, fluoroquinolones, tetracyclines, sulfon-
amides, and metronidazole [15]. In our recent expe-
rience, we have noted that cefepime neurotoxicity
may be a particularly underappreciated phenomenon in
ICUs [16].
In this study we aimed to describe the features of a
cohort of patients with cefepime neurotoxicity.
Materials and methods
This was a retrospective observational study conducted
at the Mayo Clinic in Rochester, Minnesota. We perfor-
med a preliminary search of our pharmacy database for
patients who had cefepime profiled on their medication
list during hospitalization in an ICU at our institution
between January 1, 2009 and December 31, 2011. To
identify our cohort of interest, we then entered these
results into our electronic Mayo Medical Record Retrieval
System and searched the clinical notes for diagnoses
of ‘renal failure, kidney injury, renal insufficiency, kid-
ney disease, renal disease, tubular necrosis, end-stage
renal disease (ESRD), acute tubular necrosis (ATN),
chronic kidney disease (CKD), acute kidney injury
(AKI), chronic renal insufficiency (CRI), or acute renal
failure (ARF)’ during the same time period. We also
searched for the terms ‘encephalopathy, delirium, altered
mental status (AMS), confusion, or acute confusional
state’. Adult patients who received ≥3 consecutive
days of treatment with IV cefepime in the ICU were
included.
We reviewed medical records and collected demogra-
phics, the duration of cefepime course, mean daily dose of
cefepime, serum creatinine and blood urea nitrogen
(BUN) concentrations on the first day of cefepime admin-
istration, baseline creatinine, whether hemodialysis was
required during cefepime administration, and clinical out-
come at the time of hospital dismissal. Acute kidney injury
was defined as a 1.5-fold increase from baseline creatinine
or absolute increase in creatinine by ≥0.3 mg/dL. A pa-
tient was considered to have chronic kidney disease if
their baseline estimated glomerular filtration rate (eGFR)
was ≤60 mL/min/1.73 m2 for ≥3 months. Dose adjust-
ments for renal function considered appropriate based on
the recommendations in the online Micromedex™ 2.0
database. For example, for a usual dose of 2 grams (g)
every 12 hours, if creatinine clearance (CLCr) is 30 to
60 mL/min, an appropriate adjustment is 2 g every 24
hours. If CLCr is 11 to 29 mL/min, the correct adjustment
is 1 g every 24 hours. For patients receiving continuous
renal replacement therapy, a dose ≤1 g every 12 hours was
considered appropriate, except when prescribed for theindication of febrile neutropenia or severe life-threatening
infections, in which case higher doses were considered
acceptable. This threshold was determined based on the
dosing recommendations from the Mayo Clinic anti-
microbial therapy guide, which is developed by experts in
our infectious diseases division and is updated every few
years based on the prevalence of specific organisms/
infections (and resistance rates) in units at our institution.
Medical records were reviewed to determine whether
there were neurologic symptoms that coincided with the
administration of intravenous (IV) cefepime. The likeli-
hood of causality was ascribed via a modified Delphi
method; in order for symptoms to be attributed to cefe-
pime neurotoxicity, the following criteria had to be met:
1) neurologic symptoms consisting of encephalopathy,
including decreased level of alertness, myoclonus, seizures,
or any combination of these, 2) no alternative cause for
neurological deterioration, 3) clear temporal relationship
between neurologic symptoms and cefepime administra-
tion (that is symptoms had to begin following initiation of
cefepime, persist or worsen during cefepime adminis-
tration, and improve or resolve when the medication was
discontinued). If symptoms improved spontaneously and
there was no change in cefepime dosing, they were not
attributed to cefepime. Possible cases were identified by
three abstractors (JEF, EAK, SEH). Any possible cases
were then reviewed by five co-authors (JEF, EAK, SEH,
EFW, AAR) independently. Upon review, when encephal-
opathy was attributed to cefepime by all five reviewers, the
case in question was considered a ‘definite’ case. When
four reviewers agreed, it was considered a ‘probable’ case,
and when three reviewers agreed, the case was considered
‘possible’.Standard protocol approvals, registrations, and patient
consents
This study was approved by the Mayo Clinic Institutional
Review Board. All patients included in this study had
given informed consent to use their medical records for
research purposes.Statistical analysis
Descriptive summaries were reported as mean ± stand-
ard deviation or median and interquartile range (IQR)
for continuous variables, with counts and frequencies
for categorical variables. Comparisons between sub-
groups with dichotomous or ordinal variables subgroups
were performed with chi-square test or two-sided
Fisher’s exact test. For comparisons of continuous vari-
ables, we used the Wilcoxon rank sum test. Probability
(P) values <0.05 were considered statistically significant.
We used JMP 9.0, a SAS-based statistical package (SAS
Institute, Cary, NC, USA), to analyze the data.
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A total of 100 patients were included. Mean age was
65.8 years (± 12.7 years) and 61 were men. The median
daily average dose of cefepime was 2.5 grams (IQR 2.0
to 3.5 g). Indications for antibiotic therapy are shown in
Table 1. Patients were hospitalized in the medical ICU
(n = 66), surgical ICU (n = 19), trauma ICU (n = 9), car-
diovascular ICU (n = 5), or neuroscience ICU (n = 1).
The median acute physiology and chronic health eva-
luation (APACHE) III score - available for 93% - was 85
(IQR 71.5 to 110.5) The median duration of treatment
was 6 days (IQR 4 to 10 days). Renal failure in any form
was present in 84 patients. Chronic kidney disease
affected 40 patients, and 77 had acute kidney injury.
Thirty-three patients received renal replacement therapy
during the course of cefepime. Of these, 18 underwent
continuous veno-venous hemofiltration and 15 were
treated with intermittent hemodialysis. The median
baseline creatinine of the cohort was 1.0 mg/dL (IQR 0.8
to 1.3 mg/dL). The median creatinine at the start of
cefepime therapy was 1.6 mg/dL (1.0 to 2.3 mg/dL),
median blood urea nitrogen was 41 mg/dL (IQR 26.3 to
62.5 mg/dL) and median eGFR was 34 mL/min/1.73 m2
(IQR 24.3 to 59.5 ml/min/1.73 m2). Electroencepha-
lograms (EEGs) were performed during the cefepime
course in 17 patients of the entire cohort. Findings
included moderate or severe generalized slowing in twelve
(70.6%), triphasic waves in eight (47.1%), multifocal sharp
waves in five (29.4%), burst-suppression in two (11.8%),
non-reactive alpha in one (n = 5.8%), and nonconvulsive
status epilepticus (NCSE) in 1 (5.8%).
Cefepime neurotoxicity occurred in 15 patients. Of
these, seven were considered definite cases, three prob-
able, and five possible. The daily doses of cefepime were
precisely known for 14 cases (93.3%). The dose had been
appropriately adjusted according to renal function in four
(28.6%) patients with cefepime neurotoxicity. Neurologic
symptoms began at median day 3 (range 1 to 7 days) afterTable 1 Indication for cefepime administration in 100 ICU
patients
Indication n




Urinary tract infection 3
Miscellaneous 6
Cellulitis or fasciitis 3
Endocarditis 1
Joint infection (shoulder) 1
Subdural empyema 1cefepime initiation and included depressed level of con-
sciousness (n = 13), myoclonus ( n = 11), disorientation
(n = 6), and NCSE (n = 1). Myoclonus was predominant in
the facial muscles in six patients and generalized through-
out the body in five patients. When predominant in facial
muscles, it often involved the periocular muscles, and half
of patients had concomitant involvement of one extremity
or abdominal muscles. EEGs were performed in nine
patients (60%) with cefepime neurotoxicity. The most
common findings were diffuse background slowing, tri-
phasic waves, and multifocal sharp waves (example shown
in Figure 1). Only one patient had electrographic seizures.
Detailed results of EEGs performed in these cases are
shown in Table 2.
Over two-thirds of patients (n = 72, 69.9%) died during
the hospitalization. Of those who died, 19 patients (26%)
received cefepime until their death, making it impossible
to determine if the encephalopathy may have been rela-
ted to cefepime administration.
Results comparing clinical characteristics in patients
who developed cefepime neurotoxicity and the rest of
the cohort are shown in Table 3. Patients who developed
cefepime neurotoxicity were less likely to have received
an appropriate dose reduction based on renal clearance
compared to those who did not develop neurotoxicity
(28.6% vs. 75.3%, P = 0.001) and more likely to have a
history of CKD (66.7% vs. 35.3%, P = 0.04).
Discussion
In this retrospective, single-center study of ICU patients
with renal failure, cefepime neurotoxicity was common,
particularly in this sample of mostly older patients with
pre-existing renal failure. Cefepime neurotoxicity was
significantly more frequent in patients without appropri-
ate dose adjustments for renal function compared to
those with dose reductions. The more common clinical
manifestations of cefepime neurotoxicity included im-
paired consciousness, encephalopathy, and myoclonus.
Cefepime has received recent attention regarding its
potential to cause neurologic complications, and the risk
of seizures has been particularly emphasized. In June
2012 the United States Food and Drug Administration
released a safety announcement reminding clinicians to
adjust the dose of cefepime in patients with renal
impairment because of the possibility of seizures (and
specifically, of NCSE) [17]. The report focused on seiz-
ure activity, an undoubtedly concerning adverse event.
There have been nearly 60 cases of cefepime-associated
NCSE reported, and ongoing seizure activity played a
role in at least one of these patient’s deaths [17].
Periodic sharp waves and triphasic waves are cha-
racteristically seen in cefepime neurotoxicity [6]. In
one recent study, periodic epileptiform discharges on
EEG were five times more frequent in patients receiving
Figure 1 EEG findings in cefepime neurotoxicity. Electroencephalogram (longitudinal bipolar montage) of a patient receiving intravenous (IV)
cefepime shows diffuse slowing of the background, atypical triphasic waves, and multifocal sharp waves.
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overall the prevalence of this finding was still relatively
low (1.3%) [18].
While it is imperative that health-care providers are
aware of the potential complication of seizures associated
with cefepime use, our findings indicate that seizures and
NCSE are very uncommon clinical expressions of ce-
fepime neurotoxicity. Rather, the more likely clinical
scenario is a patient who develops difficult-to-explain
‘altered mental status’, which may be either a depression in
the level of consciousness or confusion or disorientation.
Associated myoclonus and renal impairment are potentiallyTable 2 Electroencephalogram results of patients with
cefepime neurotoxicity
N EEG findings*
2 Atypical triphasic waves
2 Severe diffuse slowing
1 Triphasic waves and multifocal sharp waves
1 Stimulus-induced rhythmic sharp waves over the midline region
(SIRPIDs)
1 Multifocal and quasi-periodic sharp waves
1 Multifocal sharp waves
1 Continuous generalized sharp and slow wave discharges (NCSE)
and triphasic waves
*All EEGs additionally showed moderate-severe nonspecific diffuse slowing of
the background. EEG, electroencephalogram; SIRPIDs, stimulus-induced rhythmic,
periodic, or ictal discharges; NCSE, nonconvulsive status epilepticus.suggestive of the diagnosis and should prompt the discon-
tinuation of cefepime in favor of an alternative antibiotic.
We have observed patients with renal failure and severe
encephalopathy or coma who improved dramatically after
the cessation of cefepime. Some of these patients were
so seriously affected that discussions about withdrawal of
life-sustaining measures had occurred. Stopping a medica-
tion is a simple therapeutic trial. Because cefepime neuro-
toxicity is a reversible (and preventable) cause of severe
neurologic symptoms, it is important for clinicians to be
aware of this possibility and consider the use of alternative
antibiotics in patients with renal impairment.
Decreasing the dose of cefepime in accordance with a
patient’s estimated renal function is recommended, and
our findings support and emphasize the importance of
this recommendation. Still, cefepime neurotoxicity can
occur despite dose adjustments [19] and in our study, of
those with cefepime neurotoxicity, 28.9% (four of four-
teen patients with known doses) developed neurologic
symptoms despite a standard dose reduction based on
CLCr. It is also notable that neurotoxicity can occur des-
pite concurrent hemodialysis [20], though one expects
the neurologic symptoms to improve after a few days if
the dose has been appropriately adjusted and if flow
rates are adequate. The current practice of cefepime
dosing is dictated by standard algorithms according to
CLCr. Cefepime concentrations in the blood or cere-
brospinal fluid have been performed rarely for research
Table 3 Characteristics of 100 ICU patients receiving intravenous (IV) cefepime
Cefepime neurotoxicity Rest of cohort P value
n = 15 n = 85
Age, years, mean 69 66 0.16
Male gender, n (%) 11 (73) 50 (59) 0.39
Acute kidney injury, n (%) 13 (87) 64 (75) 0.51
Chronic kidney disease, n (%) 10 (67) 30 (35) 0.042
Hemodialysis, n (%) 4 (27) 28 (33) 0.77
Peak creatinine, median (IQR) 2.8 (1.7-3.1)* 2.3 (1.5-3) 0.36
Nadir eGFR, median (IQR) 22.5 (20.8-34.3) 27.5 (18-45) 0.53
Mean daily cefepime dose, g, median (IQR) 2.5 (1.7-4)* 2.5 (2-3.5) 0.66
Cefepime duration, days, median (IQR) 5 (4.8-7.3)* 7 (4-10) 0.26
Appropriate dose reduction for renal function, n (%) 4 (29)* 64 (75) 0.001
*Data available for 14 of the 15 cases of cefepime neurotoxicity. IQR, interquartile range; g, grams.
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practice. However, empirical dosing on the basis of one
of these algorithms may not be sufficient to prevent
accumulation of cefepime to ‘toxic’ concentrations in
certain individuals because extreme pharmacokinetic
deviations can occur while adhering to a standard algo-
rithm [21]. In one prospective study of 20 ICU patients
who received cefepime based on standard dose reduc-
tions according to CLCr, plasma cefepime concentra-
tions varied by two- to three-fold at peak levels and
up to 40-fold at trough levels [21]. In addition, dosing
medications for patients with CKD may be compli-
cated because the calculated GFR or serum creatinine
do not always correlate well with true renal function
of these patients.
There are limitations to our study. This was not a pro-
spective study of all patients in the ICU receiving cefe-
pime, and thus we cannot estimate the true incidence of
cefepime neurotoxicity in that population. While the
modified Delphi method did mandate that there was no
alternative cause of adverse neurologic symptoms, the
retrospective nature of the study makes it impossible to
know with full certainty that cefepime alone was the
cause. Other variables could have potentially con-
founded this assessment and may have been in part
responsible for symptoms that we ascribed to cefepime.
However, in addition to the criteria mandating the
exclusion of alternative causes, each potential case was
reviewed independently by five clinicians to minimize
this possibility.
In addition, EEGs were not performed in the majority
of our patients, so it is possible we underestimated the
occurrence of electrographic seizures or NCSE. Never-
theless, this may not have been clinically relevant
because the patients in our series who did not have EEGs
improved clinically with merely the discontinuation ofcefepime and many patients described in the literature
recover with simply discontinuing cefepime and without
antiepileptic therapy [8,9,12,22]. In this series, the diag-
nosis of cefepime neurotoxicity was made by clinical
assessment and consensus and we did not have blood or
CSF levels of cefepime available. While diagnosis by clin-
ical assessment more closely resembles current clinical
practice, a prospective study in which cefepime levels
are measured and correlated with clinical and electro-
physiologic data would be useful to identify a therapeutic
range that could potentially be used for drug monitoring
in the future.
Conclusions
Cefepime neurotoxicity affects critically ill patients with
chronic kidney disease and causes encephalopathy, myo-
clonus, and less commonly seizures in ICU patients. It
most commonly occurs when standard dose adjustments
for renal function are not performed, but can occur des-
pite dose adjustment in a minority of patients. Cefepime
should be discontinued in ICU patients with renal failure
who have encephalopathy if no alternative diagnosis is
more likely, given that it is a potentially reversible cause
of severe neurologic impairment.
Key messages
 Among critically ill patients, cefepime
neurotoxicity affects predominantly patients
with pre-existent kidney disease.
 Encephalopathy and myoclonus are the most
common clinical presentations of cefepime
neurotoxicity in the ICU.
 Dose adjustments for renal function are
critical to minimize the risk of cefepime
neurotoxicity.
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